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Rapport de synthèse 
Objectif: le remplacement valvulaire aortique par voie transcathétère est, actuellement, une méthode fiable indiquée 
pour des patients à haut risque porteurs d'une sténose valvulaire aortique. La voie transfémorale est utilisable 
seulement en cas d'absence de maladie vasculaire et la voie transapicale est contrindiquée en cas de dysfonction 
pulmonaire chronique sévère. Une alternative pour ne pas passer a travers l'espace pleural serait par voie sous-
xiphoïdienne et trans-septale à travers le ventricule droit. 
Méthode: une expérience animale a été amené au laboratoire de recherche du CHUV. Cinq cochons (poids : 
52.3±10.9 kg) ont été endormi et, sous anesthésie générale, le ventricule droit a été préparé a travers un accès sous-
xiphoïdien. Ensuite, sous guide fluoroscopique et avec l'utilisation d'une échocardiographie intracardiaque, un accès 
trans-septal a été crée entre le ventricule droit et le ventricule gauche en utilisant des dilatateur de diamètre croissant 
(de 8F à 26F). Par la suite, une valve stentée crée dans le laboratoire en utilisant un stent en nitinol et du péricarde a 
été chargé dans une cartouche et introduite dans le ventricule gauche à travers un introducteur trans-septal. Enfin, la 
valve a été amené dans la chambre de chasse du ventricule gauche et ensuite dans la racine aortique et puis déployé 
au bon endroit. Quand le système a été retiré, le septum ventriculaire a pu être réparé par mise en place d'un système 
d'occlusion septal Amplazer. Trente minutes après la procédure, les animaux ont été sacrifié et le cœur a été 
analysé pour étudier le positionnement da la valve stentée, l'efficacité de la fermeture du septum inter-ventriculaire 
et la fermeture de la paroi du ventricule droit. 
Résultat : les cinq cochon ont tous eu un parfait positionnement et pose de la prothèse en position aortique au 
premier essai (efficacité 100%). Les procédures ont duré, moyennement, 49±4 minutes et la progressive dilatation 
de l'accès trans-septale à donné lieu à une communication inter-ventriculaire mesurable après dilatation avec du l 8F 
et plus. Toutes les valves stentées ont été déployées au bon endroit avec un bon résultat du fonctionnement des 
valves prothétiques et absence d'insuffisance para prothétique. Pendant les procédures, des battement prématurés 
ainsi que des épisodes isolées de tachycardie supra ventriculaire ont été détectés. Par contre, il n'y a pas eu de bloc 
atrio-ventriculaire. Les pertes sanguines pendant les procédures étaient de 280±10mL, et les systèmes d'occlusion 
Amplatzer étaient tous bien déployés sans shunts inter-ventriculaires résiduels. 
Conclusion: la technique d'introduction de valve stentées par voie extrapleural (trans-ventriculaire et trans-septale) 
est techniquement possible et elle jette les bases pour le remplacement valvulaire aortique trans-ventriculaire sous 
anesthésie locale. 
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Abstract 
Objective: The aim of this study was to investigate the feasibility of transventricular-transseptal approach (TVSA) for extrapleural trans-
catheter aortic valved stent implantation via a subxyphoidian access. Methods: ln five porcine experiments (52.3 ± 10.9 kg) the right ventricle 
was exposed via subxyphoidian access. Linder the guidance of intracardiac echocardiography (ICE) and fluoroscopy, the transseptal access from 
right ventricle to left ventricle was created progressively by puncture and dilation with dilators (8F-26F). Valved stents built in-house from 
commercial tanned pericardium and self-expandable Nitinol stents were loaded into a cartridge. A delivery sheath was then introduced from the 
right ventricle into the left ventricle and then into the ascending aorta. The cartridge was connected and the valved stent was deployed in the 
aortic position. Then, the ventricular septal access was sealed with an Amplatzer septal occluder device and the right ventricular access was 
closed by tying prepared purse-string suture directly. Thirty minutes after the whole procedure, the animals were sacrificed for macroscopic 
evaluation of the position of valved stent and septal closure device. Result: Procedural success of TVSA was 100% at the first attempt. Mean 
procedure time was 49 ± 4 min. Progressive dilatation of the transseptal access resulted in a measurable ventricular septal defect (VSD) after 
dilator sizes 18F and more. All valved stents were delivered at the target site over the native aortic valve with good acute valve function and no 
paravalvular leaks. During the procedure, premature beats (5/5) and supraventriclar tachycardias (5/5) were observed, but no atrial-ventricular 
block (0/5) occurred. Heart rate before (after) was 90 ± 3 beats min-1 (100 ± 2 beats min-1: p < 0.05), whereas blood pressure was 
60 ± 1 mm Hg (55 ± 2 mm Hg (p < 0.05)). Total blood loss was 280 ± 10 ml. The Amplatzer septal occluder devices were fully deployed and 
the ventricular septal accesses were sealed successfully, without detectable residual shunt. Conclusion: Trans-catheter implantation of aortic 
valved stent via extrapleural transventricular-transseptal access is technically feasible and has the potential for a simplified procedure under 
local anaesthesia. 
© 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved. 
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1. Introduction 
Trans-catheter aortic valve implantation (TAVI) [1] is 
growing rapidly and it has been demonstrated for the trans-
apical route [2,3] that an excellent result can be achieved 
with minimal risk of stroke or atrial-ventricular block [4,5], 
and, of course no damage of access vessels. However, the 
trans-apical route has so far been realised through a mini-
thoracotomy, which, in turn, requires general anaesthesia. 
We have previously reported a video-endoscopic approach 
[6], which has been realised in the experimental setting in 
combination with modified closure devices [7,8] to achieve 
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rapid sealing of the trans-apical access orifice. Although this 
approach is less invasive, it is still a transpleural route with 
all its limitations. 
The opening of the pleural space can be avoided with a 
subxyphoid access, and we have used this route for 
implantation of a stent valve into a right ventricle (RV)-
pulmonary artery conduit with a degenerated valve by 
puncture of the right ventricle [9]. ln the experimental 
setting, we have also reached the left ventricle and the aorta 
from a subxyphoid or rather a trans-umbilical approach to 
implant an aortic stent-valve through a natural orifice [10] 
for namely, Natural Orifice Translumenal Endoscopie Surgery 
[11 ]. lnterestingly enough, the pulmonary artery and the 
aorta could be accessed both in reproducible fashion with this 
experimental single port approach in combination with 
closure devices for sealing of the transparietal ventricular 
access orifices. 
ln the clinical setting, however, it appears to be more 
difficult to access the left ventricle with a subxyphoid 
technique because of the natural position of the human 
1010-7940/$ - see front matter © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved. 
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heart, which tends to expose mainly the right ventricle in the 
antero-diaphragmatic position, whereas the left ventricle is 
usually latero-posterior. Hence, the idea was to approach the 
aortic root in transventricular-transseptal fashion by passing 
through the right ventricle and the septum to reach the left 
side and ultimately the aortic route. 
2. Materials and methods 
2.1. Valved stent construction 
The valved stents used in this study were built from two 
components: a double-crowned [12] self-expandable Nitinol 
stent [13] with a waist diameter of 25 mm (Symetis SA, 
Lausanne, Switzerland, shown in Fig. 1 (D)) and inside a 
pericardial valve, which was made in-house from glutar-
aldehyde-preserved equine pericardium as shown in 
Fig. 1 (A)-(C)). ln vitro bench tests were realised with the 
Dynatek Dalta MP3 system as previously reported [13]. 
2.2. De/ivery system 
The stent-valve delivery system was based on a commer-
cial introducer for trans-apical aortic valve implantations 
with an externat diameter of 30F and total length of 22 cm, 
which was modified for use with a self-expanding stent-valve 
design by adding a pusher with a blunt tip. The valved stent 
was compressed with a commercial crimper over a guide wire 
and a catheter, and loaded into a cartridge. Once the 
introducer was positioned in transventricular-transseptal 
fashion, the cartridge was connected to the valved sheath 
and the stent valve was transferred with the pusher. No 
balloon was necessary to deliver the thermosensitive Nitinol 
stent, which expanded immediately as soon as it was released 
from the sheath. 
2. 3. Access closure device 
An Amplatzer muscular septal occluder (AGA Medical 
Corp, Golden Valley, MN, USA), which is made of woven 
Fig. 1. The self-expandable valved Nitinol stent, which consisted of a self-
expandable Nitinol stent (D) and a homemade equine pericardial trileaflet 
valve with single point attachment (A, B and C). 
Nitinol wires into two self-expandable round concave 
retention disks with a connecting 7-mm waist, was used to 
seal the transventricular septal access after the deployment 
of the aortic valved stent. To pass more easily through the 
ventricular septal access, the Amplatzer delivery system was 
modified to allow for a monorail technique. After implanta-
tion of the aortic valved stent, the same guide wire was used 
to insert the closure device for sealing off the transseptal left 
ventricular access. 
All of the above devices underwent thorough in vitro 
testing prior to the experimental in vivo implantation. All 
animais received care in compliance with 'the Principles 
of Laboratory Animais' formulated by the National Society of 
Medical Research and 'the Guide for the Care and Use of 
Laboratory Animais' prepared by the lnstitute of Laboratory 
Animal Resources and published by the National lnstitute of 
Health (NIH publication 85-23, revised 1985). The protocol 
was approved by the State Committee on Animal Research. 
2.4. Surgical access 
An acute in vivo evaluation was performed in five porcine 
experiments, aged from 9 to 12 weeks, with a mean body 
weight of 52.3 ± 10.9 kg. Before the procedure, general 
anaesthesia was induced with 22 mg kg-1 ketamine, 
0.8 mg kg-1 atropine administered intramuscularly, and 
15 mg kg-1 thiopental administered through a superficial vein 
of the right ear. Linder general anaesthesia maintained with 
volatile anaesthetics, and mechanical ventilation, bilateral 
internai jugular veins and arteries were exposed. An 
intravenous line was placed in the right jugular vein. Then, 
the arterial pressure line was inserted into the right carotid 
artery. The left jugular vein was mobilised for the insertion of 
an intracardiac echocardiographic probe (ICE: Accuson 
Navigate, Accuson, Siemens, Munich, Germany). Continuous 
monitoring of electrocardiography, arterial pressure, central 
venous pressure and oxygen saturation was routine. The 
subxyphoid to paraxyphoid area was prepared and a 5-cm 
incision was made. Then, the diaphragmatic face of the right 
ventricle was exposed. A double 2/0 purse-string monofila-
ment suture reinforced with felt pledgets was prepared in a 
zone of myocardium, without coronary arteries, on the 
diaphragmatic side of the right ventricle. 
2.5. Transventricular-transseptal aortic valved stent 
implantation 
First, the left ventricular outflow tract dimensions and the 
native aortic valve, including annular diameter, valvular 
surface and morphology of the aortic root were visualised and 
measured by intracardiac ultrasound. Then, a valved stent of 
optimal size was crimped and loaded into the delivery 
cartridge as outlined above. After systemic heparinisation 
(Liquemine®, Roche, Switzerland: 100 IU kç1), theprepared 
area of right ventricle was punctured with a needle, followed 
by a guide wire, and then an over-the-wire 8F introducer 
system (Arrows, Reading, PA, USA) was inserted crossing the 
right ventricular cavity and the ventricular septum into the 
left ventricle. Linder ICE and fluoroscopic guidance, a soft-tip 
J-type STARTER guide wire (0.035 inches, 180 cm; Boston 
Scientific, Natick, MA, USA) was first introduced into the left 
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Fig. 2. The set of dilators used in this experiment, from 12F to 26F in size. 
ventricle, then crossed the aortic annulus, and finally 
advanced into the descending aorta. Next, the soft-tip guide 
wire was exchanged with a pig-tail catheter for a Lunderquist 
extra stiff back-up guide wire (TSMG-35-260-LES, Cook 
Medical, Limerick, lreland). A series of dilators with 
progressive diameters ranging from 12F to 26F was used to 
dilate the ventricular transseptal access up to the optimal 
size required for TAVI (shown in Fig. 2). At each step, the 
electrocardiogram and the haemodynamic parameters were 
recorded continuously, and the ventricular septum was 
monitored in real time under ICE to assess the dimensions 
of the ventricular septal defects (VSDs) and the shunt 
between the left and right ventricles. 
Finally, the 30-F sheath was positioned in ascending aorta 
through the right ventricle-left ventricle (RV-LV) transsep-
tal route. The cartridge with the preloaded stent valve was 
connected and transferred into the sheath as previously 
described. Once the stent valve could be identified by 
fluoroscopy in the ascending aorta, the sheath was slowly 
pulled back, and the stent valve was released in a stepwise 
fashion at the predetermined level of the aortic annulus. 
2.6. Closure of bath the ventricular access and the septa/ 
access 
Linder the guidance of ICE and fluoroscopy, a delivery 
sheath with an optimally sized muscular Amplatzer occluder 
device was inserted over the Lunderquist guide wire into the 
left ventricle. Then, the Amplatzer device was advanced 
within its sheath, while the 30-F sheath was withdrawn, until 
the left of the occluder disk was deployed on the left side of 
ventricular septum (in the left ventricle). Further retraction 
of the sheath over the delivery cable allowed the right dise to 
be deployed on the right side of the ventricular septum (in 
the right ventricle). At the end, the right ventricular access 
was closed by tying the purse-string sutures prepared at the 
beginning of the procedure. 
2.7. Assessment of devices' position and function 
The position and function of valved stent and Amplatzer 
septal occluder were assessed after their deployment for 
30 min by ICE. Then, animals were sacrificed to re-examine 
the position of the valved stents and the Amplatzer device at 
necropsy. 
Data were analysed with SPSS software (Statistical 
Package for the Social Sciences). Continuous variables were 
Fig. 3. Under fluoroscopy, the ventricular septal access was dilated with a 20 
French dilator, by following the super stiff back-up guide wire. 
reported as mean ± SD. Paired Student's t-tests was used for 
comparison, where applicable, each animal being its own 
control. 
3. Results 
Procedural success of transventricular-transseptal TAVI 
was 100% (5/5 animals). Mean procedure time was 
49 ± 4 min. Transventricular-transseptal access was 
straightforward and there was not much difficulty to deliver 
the guide wire crossing aortic annulus into the ascending 
aorta under fluoroscopy. By following the guide wire, the 
ventricular septal access was dilated progressively from 8F 
up to 26F (Fig. 3). 
Linder ICE, the manipulations for dilation were monitored 
and the ventricular septal access was evaluated each time. 
Obvious blood shunts between the left and right ventricle 
would not appear, until the septal accesses were dilated with 
the 18F and over-sized dilators (Fig. 4). The size of acquired 
ventricular septal defects (aVSD) was assessed at each step, 
following the guide wire with ICE. 
The mean diameter of native aortic annulus in pigs was 
21.9 ± 0.4 mm. All valved stents were delivered at the target 
site with good acute valve function. Likewise, the Amplatzer 
septal occluder devices were fully deployed and the 
ventricular septal accesses were sealed successfully 
(Figs. 5 and 6). All animals were in sinus rhythm before 
·and after the transventricular-transseptal aortic valve 
implantation and device closure of the VSD. However, during 
the procedure, the following electro-mechanical events 
were recorded: atrial premature beat 5/5, ventricular 
premature beat 4/5, sino-tachyarrhythmia 5/5, ST segment 
elevation 1 /5 and atrioventricular black 0/5. Likewise, the 
haemodynamics were relatively stable. The heart rate was 
638 L. Liu et al. I European Journal of Cardio-thoracic Surgery 39 (2011) 635-642 
Fig. 4. After the ventricular septal access was dilated with 18F and oversized 
dilators, an obvious blood shunt from left ventricle to the right ventricle can be 
demonstrated with ICE and the colour-Doppler. 
90 ± 3 beats min-1 before and 100 ± 2 beats min-1 after the 
procedure (p < 0.05), whereas the arterial pressure was 
assessed before (60 ± 1 mm Hg) and after the procedure 
(55 ± 2 mm Hg: p < 0.05). 
No animal had significant regurgitation or paravalvular 
leak after implantation on ICE analysis. ICE demonstrated the 
complete opening and closing of the implanted valves. There 
were also no residual shunts detectable between the two 
ventricles after deployment of Amplatzer septal occluder 
device. 
Macroscopic analysis of valved stents in the a ortie position 
confirmed the adequate positioning within the defined 
landing zone, without left ventricular outflow tract obstruc-
tion and no damage to the ascending aorta or structural 
Fig. 5. Delivering the valved stent in the aortic annulus under the guidance of 
fluoroscopy (from A to C). The valved stent and ventricular septal occluder (D) 
were correctly positioned after deployment (indicated with arrows). 
Fig. 6. Under ICE the valved stent was in aortic position with good function (A, 
indicated with an arrow). The Amplatzer septal occluder device was deployed 
in the accurate position, the ventricular septal access (B, the left disk of 
Amplatzer closure device in the left ventricle, indicated with an arrow). 
defects of the valved stents was found at necropsy (Fig. 7). 
The ventricular septal access was closed completely by the 
Amplatzer septal occluder device, on gross visual examina-
tion (Fig. 7). 
Fig. 7. At necropsy the valved stent was in the correct position ([], without 
displacement of anterior leaflet of mitral valve and the outflow tract of left 
ventricle was normal without obstruction (A, valved stent D; outflow tract of 
left ventricle -+). No damage to the ascending aorta or structural defects of 
the valved stents was found at necropsy (Band C, valved stent r-; Amplatzer 
closure device -+), There were obvious fingerprints of stent after the valved 
stent was removed and confirmed again the valved stent was correctly 
positioned in the aortic annulus (D, fingerprints of the valved stent C; 
Amplatzer closure device-+ ). 
L. Liu et al. / European Journal of Cardio-thoracic Surgery 39 (2011) 635-642 639 
4. Discussion 
The subxyphoid, transventricular-transseptal approach to 
the aortic root appears to be a promising new route for less 
invasive TAVI. lnterestingly enough, only min or cardiac rhythm 
disturbances occurred during our experiments, although the 
porcine model is known for its arrhy~hmia and its f:agile 
haemodynamics. As demonstrated prev1ously, the left s1de of 
the heart is easily accessed through a subxyphoid incision in the 
pig [1o,11 ]. Such situation occurs to a less extent in the clinicat 
setting where mainly the diaphragmatic side of the right 
ventricle is exposed from this incision. We have successfully 
used the subxyphoid transventricular (RV) approach for clinicat 
trans-catheter pulmonary valve implantation [9]. We were 
impressed by the ease of recovery and the fact that this 
procedure had been realised without opening of the pleural 
space and therefore it appeared that there was no need for 
either intubation or pleural drainage. 
The subxyphoid approach is well known to cardiac 
surgeons not only for pericardial drainage [14], but also 
for implantation of epicardial pacemaker leads. Sorne of 
these procedures can also be realised with endoscopie 
techniques [15, 16] which have also been demonstrated for 
trans-apical aortic valve implantation [6]. The most intri-
guing finding is, of course, that the subxyphoid route has also 
been used in awake patients for coronary artery bypass 
grafting in high risk patients [17], indeed very similar to the 
patients we have for TAVI. 
Hence, our interest in a transventricular-transseptal 
route to the aortic root and TAVI, which may provide again a 
number of interesting advantages such as: 
1. an extrapleural access; 
2. no need for intubation; 
3. no need for general anaesthesia; and 
4. potential for NOTES (trans-umbilical access). 
With the present study, we have been able to show, that 
technically, the transventricular-transseptal approach is not 
only feasible but also that the aortic root can be reached 
from the right ventricle in a reliable fashion and that the 
delivery of a clinicat sized stent-valve can be achieved with 
good functional results. 
Of course, trans-apical TAVI is still an excellent and 
technically mature procedure with rare local complications 
and satisfying mid-term follow-up results. All of these 
findings do not preclude the already established advantages 
of antegrade trans-apical TAVI including superior device 
performance (less compromise required for smaller intro-
ducer diameters required for peripheral access route), better 
implantation control (shorter delivery systems, relatively 
straight access), as well as lower risk of stroke, atrioven-
tricular block and vascular complications as compared with 
peripheral retrograde routes. 
Of course, there are also potential limitations for the 
transventricular-transseptal approach to the aortic root. 
These include the obviously necessary temporary VSD and its 
potential problems including: 
1. to create transseptal access means increasing additional 
traumatic complications to the heart; 
2. arrhythmias during the procedure; 
3. haemodynamic consequences of a temporary VSD; 
4. problems of device delivery due to suboptimal alignment; 
5. feasibility of the device closure, and the reliability of the 
right ventricular access closure, which might add 
additional costs to the patients; 
6. potential risk of residual VSD, etc. 
As outlined above, and very much to our surprise, 
arrhythmias appeared not to be a problem in this experi-
mental set-up, and also the temporary VSD appeared to be 
manageable. As a matter of fact, only the dilator sizes of 18F 
and more resulted in a detectable VSD during ICE. This is in 
line with the knowledge compiled from atrial transseptal 
procedures, where smalt atrial septal defects (ASDs) created 
for diagnostic and/ or therapeutic purposes do usually not 
require closure devices [18]. ln addition, we allowed here for 
a stabilisation period to assess the sizes/consequences of the 
VSDs between the dilators of increasing size, whereas for the 
clinicat setting, we would certainly replace immediately 
each dilator with the next one and therefore allow between 
the steps only for minimal time period of shunting due to the 
VSD. Furthermore, one can expect some degree of septal 
hypertrophy in clinicat cases with severe aortic stenosis, 
which, in turn, will induce a longer intraseptal route and 
therefore reduce the potential for shunting, correspondingly. 
With regard to suboptimal device alignment due to the 
eccentric initial puncture, we did not, in fact, encounter any 
problem with device delivery, which was always smooth. 
Likewise, antegrade exploration of the aortic root with a soft 
J-type guide wire at the beginning of the procedure was 
straightforward. lt may be of interest to revise the perceived 
impression, that the trans-apical roùte to the aortic root is 
perfectly straight. As a matter of fact, a quite significant 
angulation can occur as shown in Fig. 8, where the apical 
access spot and the aortic annulus look perfectly aligned in 
the antero-posterior projection, but the lateral view 
provides a very different reality. As a matter of fact, there 
is an angle of at least 60° in this patient with excellent 
outcome. Hence, a moderate angle of 30° or less, which is 
typically seen with the transventricular-transseptal route, 
appears not to be a problem and is of course much less than 
what is observed with the peripheral access routes where 
several curves occur, which may exceed 180°. 
Therefore, transventricular-transseptal TAVI via a sub-
xyphoidian access might have the following unique advan-
tages: 
• There is no manipulation within pleural space. Therefore, 
one can expect less interference with the respiratory 
system. This is especially suitable for patients with 
concomitant respiratory diseases and poor pulmonary 
function, or those who have received prior operations 
within the left thoracic cavity or on the left ventricle (such 
as, left ventricular aneurysmectomy), with severe pleural 
adhesions or pericardial adhesions, which can make 
exposure of the apex of the heart more difficult. 
• lt provides a possibility ofTAVI under epidural and/or local 
anaesthesia without the requirement of intubation, which 
will further minimise invasiveness and benefit patients' 
rehabilitation. 
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Fig. 8. Although an anterior-posterior chest view suggest an almost perfect 
alignment between the apical access and the aortic annulus, this is not 
necessarily true. As a matter of fact, the left lateral radiograph after 
trans-apical aortic valved stent implantation shows that the direction of 
trans-apical procedure is not parallel to the axis of aortic annulus and there 
is an obvious angle between them. 
• By using the principle of NOTES in combination with the 
transventricular-transseptal access, an access route via 
the umbilicus is more feasible, provided closure tight 
devices become available. 
• Easier to control bleeding from right ventricular access. 
The transventricular-transseptal access is on the right 
side of the heart with lower blood pressure, compared with 
the left ventricle, which, in turn, makes closure easier not 
only with sutures, but also by the means of closure devices. 
ln this experiment, no difficulties were encountered during 
closure of right ventricular access. 
ln short, transventricular-transseptal access for TAVI is a 
navel experimental exploration, which might enrich the 
routes for trans-catheter aortic valved stent implantation. 
Theoretically, it might be applied to those patients without 
indications for 'traditional' approaches (such as, transfe-
moral or trans-apical) TAVI. Considering the anatomie 
differences between human heart (patient's diseased heart) 
and swine heart, further researches will be carried out before 
its possible clinical application. 
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Editorial comment 
Why doit the easy way? 
Keywords: Trans-apical; Aortic-valve implantation 
With the event of trans-catheter aortic-valve implanta-
tion, the left-ventricular trans-apical access has gained 
renewed interest. White most studies report very few 
access-related complications, one recent study reports 
bleeding in 5% and formation of late pseudo-aneurysms in 
6.6% of cases [1]. ln rare cases (smalt ventricle, fragile 
tissue), rupture of the left-ventricular apex can occur and 
eventually lead to a fatal outcome [2]. lt is therefore of 
interest to explore alternative direct cardiac access sites for 
aortic-valve implantation. The subxyphoid approach has 
been successfully used for single-port epicardial ablation of 
atrial fibrillation, and transabdominal, transdiaphragmatic 
endoscopie bypass grafting has been explored in an 
experimental setting [3]. 
ln this issue, Liu et al. present a new method for 
subxyphoidal right·ventricular access for transseptal aor-
tic-valve implantation [4]. White the authors have to be 
congratulated for their continuing and pioneering effort in 
developing devices to facilitate trans-apical aortic-valve 
implantation, this approach seems a little bit circumstan· 
tial. lt is argued that opening the pleura can be avoided 
using a subxyphoidal approach and that general anesthesia 
may therefore no longer be needed. The requirement of 
general anesthesia for trans-apical aortic-valve implanta· 
tion is continuously brought forward as a disadvantage 
when compared with the transfemoral access, which is now 
more often performed in local anesthesia. However, it has 
already been demonstrated that standard trans·apical 
aortic-valve implantation through the 5th or 6th left 
intercostal space can also be performed in the awake, 
spontaneously breathing patient using high epidural 
analgesia and despite pleural opening. However, there 
are other good reasons to favor general anesthesia in the 
setting of trans·catheter valve implantation. First, severe 
and life·threatening complications requiring cardiopul· 
monary bypass or cardiopulmonary resuscitation (CPR) can 
occur during the procedure at anytime. This can be 
managed more easily if the patient is already intubated. 
Second, uncontrolled motion of the patient during valve 
deployment can unarguably lead to valve dislocation, a 
problem that can easily be avoided if the patient is asleep. 
Not general anesthesia itself, but prolonged ventilation is 
disadvantageous for the patient. Trans·catheter valve 
implantation should therefore go in hand with a fast·track 
anesthesia concept, applying short-acting anesthetics and 
early extubation. 
The creation of an iatrogenic ventricular septal defect 
(VSD) is required for the proposed access. White this was 
successfully treated with the application of an Amplatzer 
occluder, the reasonableness of means can be put to 
question. Percutaneous closure of a VSD is associated with 
a relatively high risk of both peri-interventional and 
potential long·term complications. These include, but are 
not limited to, incomplete closure with residual shunt, the 
risk of device embolisation and migration, thrombo· 
embolie complications (pulmonary and systemic), hemo· 
lysis, arrhythmias and the risks associated with the need 
for anticoagulation are added to the procedure. Trans· 
catheter valve implantation is already expensive; the 
addition of devices to treat access-related collateral 
damage would further increase the economic burden. 
For cases in whom standard aortic·valve replacement is 
truly not an option and neither the transfemoral, transsub· 
clavian nor the trans-apical approach is feasible, a direct 
trans-aortic approach may be useful [5]. We must also accept 
that, even in 2010, some patients may be served best with no 
intervention at all. 
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